Press Release:

CYTOCHROMA TO PRESENT AT TWO UPCOMING INVESTOR CONFERENCES

Markham, Ontario, Canada — September 2, 2009 — Cytochroma today announced that Charles W. Bishop, PhD, President and CEO, will be presenting a corporate overview at the following investor conferences:

• Baird’s 2009 Health Care Conference at 12:45 PM EDT on Wednesday, September 9, 2009 at the Four Seasons Hotel in New York City.
• Thomas Weisel Partners’ 2009 Healthcare Conference at 10:20 AM EDT on Friday, September 11, 2009 at the Four Seasons Hotel in Boston.

About Cytochroma

Cytochroma is a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary products to treat and prevent the clinical consequences of vitamin D insufficiency and secondary hyperparathyroidism (SHPT) associated with chronic kidney disease (CKD). The Company specializes in developing new vitamin D therapies which are designed to safely and effectively treat patients with stage 3, 4 or 5 CKD.  Cytochroma has three lead product candidates in clinical development for CKD patients: CTA018 Injection and CTAP201 Injection are being developed for the treatment of SHPT in stage 5 CKD, while CTAP101 Capsules are being developed for the treatment of vitamin D insufficiency and associated SHPT in stage 3 and 4 CKD.  In addition, Cytochroma is developing novel therapies to treat hyperphosphatemia in CKD patients.

For information contact:

Cytochroma Investors:
Gordon Ngan
Executive Director, Corporate Development
Tel: +1 (905) 479-5306 ext. 333
gngan@cytochroma.com

Cytochroma Media:
Robert Stanislaro (FD)
Tel: +1 (212) 850-5657
robert.stanislaro@fd.com

< go back >